CDX-301 Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: Flt3 Ligand

Filter by location:

Los Angeles, California1 trial

Converting HR+ Breast Cancer Into an Individualized Vaccine

Cedars-Sinai Medical Center

Phase 2

Chicago, Illinois1 trial

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

University of Chicago Comprehensive Cancer Center

Phase 1

Boston, Massachusetts1 trial

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Dana-Farber Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.